rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy

doi:10.3748/wjg.v17.i38.4289

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 38

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4167)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-5) series.

Item

Count

PDF

328

HTML

3250

Figures (1-5)

309

Tables (1-5)

280

Sum=4167

Oct 14, 2011 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Oct 14, 2011; 17(38): 4289-4297
Published online Oct 14, 2011. doi: 10.3748/wjg.v17.i38.4289

Table 1 p53 expression in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	11.83 ± 1.02^e^b	8.67 ± 1.35^e^b	6.36 ± 1.62^e^b
rAd-p53	5 × 10⁶	0	36.65 ± 1.04^c^a	25.13 ± 2.73^c^a	21.26 ± 1.07^c^a
	5 × 10⁷	0	40.32 ± 1.03^c^a	32.45 ± 2.35^c^a	25.35 ± 1.28^c^a
	5 × 10⁸	0	48.86 ± 1.26^c^a	38.25 ± 2.16^c^a	29.67 ± 1.31^c^a
	5 × 10⁹	0	60.38 ± 1.14^c^a	49.37 ± 1.07^c^a	33.25 ± 2.05^c^a
rAd-p53 + OXA	5 × 10⁶	3.2	37.23 ± 1.07^e^c^a	26.54 ± 1.53^e^c^a	22.17 ± 1.13^e^c^a
	5 × 10⁷	3.2	39.83 ± 1.32^e^c^a	34.17 ± 1.26^e^c^a	24.83 ± 1.07^e^c^a
	5 × 10⁸	3.2	49.03 ± 1.26^e^c^a	40.28 ± 1.43^e^c^a	30.45 ± 1.32^e^c^a
	5 × 10⁹	3.2	61.54 ± 1.18^e^c^a	50.37 ± 1.27^e^c^a	35.21 ± 2.1^e^c^a
Control	0	0	12.55 ± 1.15	8.23 ± 1.13	6.15 ± 1.36

^aP < 0.05 vs control,

^bP > 0.05 vs control;

^cP > 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^eP < 0.05, OXA vs rAd-p53 + OXA with the same dose of OXA.

Table 2 Bax expression in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	73.52 ± 0.83^e^a	56.43 ± 0.74^e^a	36.47 ± 1.21^e^a
rAd-p53	5 × 10⁶	0	63.25 ± 1.32^c^a	53.86 ± 1.54^c^a	33.71 ± 1.41^c^a
	5 × 10⁷	0	76.14 ± 0.73^c^a	59.32 ± 1.45^c^a	39.47 ± 1.03^c^a
	5 × 10⁸	0	79.62 ± 1.46^c^a	64.74 ± 1.08^c^a	41.35 ± 1.15^c^a
	5 × 10⁹	0	82.54 ± 1.28^c^a	69.53 ± 1.02^c^a	43.75 ± 1.1^c^a
rAd-p53 + OXA	5 × 10⁶	3.2	78.82 ± 0.88^e^c^a	58.64 ± 1.07^e^c^a	49.15 ± 1.04^e^c^a
	5 × 10⁷	3.2	84.32 ± 1.02^e^c^a	62.74 ± 1.19^e^c^a	52.9 ± 1.31^e^c^a
	5 × 10⁸	3.2	87.41 ± 1.03^e^c^a	67.38 ± 1.14^e^c^a	55.23 ± 1.06^e^c^a
	5 × 10⁹	3.2	89.71 ± 0.36^e^c^a	75.14 ± 1.65^e^c^a	58.67 ± 1.12^e^c^a
Control	0	0	26.32 ± 1.04	19.91 ± 0.87	16.74 ± 1.23

^aP < 0.05 vs control;

^cP < 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^eP < 0.05, OXA vs rAd-p53 + OXA with the same dose of OXA.

Table 3 Bcl-2 expression in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	26.32 ± 1.21^e^a	47.53 ± 1.13^e^a	56.64 ± 1.33^e^a
rAd-p53	5 × 10⁶	0	28.62 ± 1.07^c^a	58.23 ± 1.04^c^a	61.23 ± 1.07^c^a
	5 × 10⁷	0	24.34 ± 1.05^c^a	46.26 ± 1.31^c^a	49.54 ± 1.14^c^a
	5 × 10⁸	0	18.62 ± 1.32^c^a	40.81 ± 1.15^c^a	47.34 ± 1.06^c^a
	5 × 10⁹	0	15.37 ± 1.51^c^a	38.37 ± 1.08^c^a	44.31 ± 1.03^c^a
rAd-p53+ OXA	5 × 10⁶	3.2	21.76 ± 1.16^e^c^a	35.63 ± 1.41^e^c^a	38.18 ± 1.08^e^c^a
	5 × 10⁷	3.2	18.34 ± 1.24^e^c^a	32.37 ± 1.07^e^c^a	35.71 ± 2.02^e^c^a
	5 × 10⁸	3.2	16.22 ± 1.02^e^c^a	29.27 ± 1.13^e^c^a	32.91 ± 1.24^e^c^a
	5 × 10⁹	3.2	13.14 ± 1.07^e^c^a	26.74 ± 1.02^e^c^a	29.84 ± 1.57^e^c^a
Control	0	0	38.97 ± 1.06	73.71 ± 2.02	84.03 ± 1.02

^aP < 0.05 vs control;

^cP < 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^eP < 0.05, OXA vs rAd-p53 + OXA with the same dose of OXA.

Table 4 Caspase-3 expression in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	12.32 ± 0.8^e^a	11.21 ± 1.05^e^a	8.86 ± 1.01^e^a
rAd-p53	5 × 10⁶	0	7.89 ± 1.13^c^a	6.07 ± 0.97^c^a	4.32 ± 1.03^c^a
	5 × 10⁷	0	10.03 ± 1.03^c^a	8.38 ± 1.04^c^a	6.03 ± 0.99^c^a
	5 × 10⁸	0	12.34 ± 1.05^c^a	10.52 ± 0.89^c^a	8.31 ± 1.02^c^a
	5 × 10⁹	0	15.04 ± 1.03^c^a	11.34 ± 0.55^c^a	10.12 ± 1.01^c^a
rAd-p53 + OXA	5 × 10⁶	3.2	22.05 ± 1.01^e^c^a	15.67 ± 1.03^e^c^a	13.48 ± 1.01^e^c^a
	5 × 10⁷	3.2	25.13 ± 1.06^e^c^a	18.83 ± 1.02^e^c^a	15.32 ± 1.07^e^c^a
	5 × 10⁸	3.2	27.24 ± 1.73^e^c^a	21.07 ± 1.01^e^c^a	18.93 ± 1.06^e^c^a
	5 × 10⁹	3.2	35.67 ± 1.03^e^c^a	26.16 ± 1.05^e^c^a	22.34 ± 1.13^e^c^a
Control	0	0	1.32 ± 1.02	1.29 ± 0.97	1.27 ± 0.68

^aP < 0.05 vs control;

^cP < 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^eP < 0.05, OXA vs rAd-p53 + OXA with the same dose of OXA.

Table 5 Apoptotic rate in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	33.52 ± 1.6^e^a	23.28 ± 1.35^e^a	18.72 ± 1.61^e^a
rAd-p53	5 × 10⁶	0	7.89 ± 1.13^c^a	6.51 ± 0.97^c^a	4.07 ± 0.83^c^a
	5 × 10⁷	0	12.47 ± 1.43^c^a	8.78 ± 1.34^c^a	6.43 ± 0.79^c^a
	5 × 10⁸	0	21.84 ± 1.05^c^a	14.24 ± 0.89^c^a	11.72 ± 1.12^c^a
	5 × 10⁹	0	36.73 ± 1.03^c^a	28.64 ± 1.75^c^a	21.82 ± 1.81^c^a
rAd-p53 + OXA	5 × 10⁶	3.2	42.38 ± 1.51^e^c^a	35.72 ± 1.13^e^c^a	28.84 ± 1.21^e^c^a
	5 × 10⁷	3.2	54.84 ± 1.26^e^c^a	48.63 ± 1.62^e^c^a	34.51 ± 1.47^e^c^a
	5 × 10⁸	3.2	58.41 ± 1.13^e^c^a	51.71 ± 1.41^e^c^a	38.5 ± 1.16^e^c^a
	5 × 10⁹	3.2	63.91 ± 1.23^e^c^a	55.73 ± 1.35^e^c^a	42.92 ± 1.33^e^c^a
Control	0	0	4.67 ± 1.32	1.74 ± 0.67	1.15 ± 0.58

^aP < 0.05 vs control;

^cP < 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^eP < 0.05, OXA vs rAd-p53 + OXA at the same dose of OXA.

Citation: Chen GX, Zheng LH, Liu SY, He XH. rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy. World J Gastroenterol 2011; 17(38): 4289-4297
URL: https://www.wjgnet.com/1007-9327/full/v17/i38/4289.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i38.4289